Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats

Hypertension

Volumn 35, Issue 5, 2000, Pages 1074-1077

  Siragy, Helmy M ^a   De Gasparo, Marc ^b   Carey, Robert M ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Bradykinin; Cyclic GMP; Nitric oxide; Receptors, angiotensin II; Valsartan

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BRADYKININ B2 RECEPTOR ANTAGONIST; CYCLIC GMP; ICATIBANT; NITRATE; NITRIC OXIDE; NITRITE; VALSARTAN;

ADOLESCENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HYPOTENSION; KIDNEY; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM RESTRICTION;

EID: 0034115730     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.35.5.1074     Document Type: Article

References (17)

1. Navar GL, Imig ID, Zou L, Wang CT. Intrarenal production of angiotensin II. Semin Nephrol. 1997;17:412-422.
2. Campbell DJ. Endogenous angiotensin II levels and the mechanism of action of angiotensin converting enzyme inhibitors and angiotensin receptor type 1 antagonists. Clin Exp Pharmacol Physiol Suppl. 1996;3: S125-S131.
3. Fricker AF, Nussberger J, Meilenbrock S, Brunner HR, Burnier M. Effect of indomethacin on the renal response to angiotensin II receptor blockade in healthy subjects. Kidney Int. 1998;54:2089-2097.
4. Siragy HM. Evidence that intrarenal bradykinin plays a role in regulation of renal function. Am J Physiol. 1993;265:E648-E654.
5. 2. J Clin Invest. 1996;97:1978-1982.
6. 2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest. 1997;100:264-269.
7. 2 receptor in a renal wrap hypertension model. Hypertension. 1999;33:1237-1242.
8. Sealy JE, Laragh JH. How to do a plasma renin assay. Cardiovasc Med. 1980;20:947-957.
9. Wirth K, Hock FJ, Albus U, Linz W, Albermann HG, Anagnostopoulos H, Henke ST, Breipohl G. König W, Knolle J, Schölkens BA. HOE 140, a new potent and long acting bradykinin antagonist: in vivo studies. Br J Pharmacol. 1991;102:774-777.
10. Siragy HM, Howell NL, Ragsdale NV, Carey RM. Renal interstitial fluid angiotensin modulation by anesthesia, epinephrine, sodium depletion, and renin inhibition. Hypertension. 1995;25:1021-1024.
11. 2, and cyclic guanosine 3′,5′-monophosphate: effects of altered sodium intake. Hypertension. 1994;23: 1068-1070.
12. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature. 1988;333:664-666.
13. Bunkenburg B, Schnell C, Baum HP, Cumin F. Wood JM. Prolonged angiotensin II antagonism in spontaneously hypertensive rats: hemodynamic and biochemical consequences. Hypertension. 1991;18:278-288.
14. Carretero OA, Scicli AG. The renal kallikrein-kinin system. Am J Physiol. 1980;238:F247-F255.
15. Fulton D, McGiff JC, Quilley J. Contribution of NO and cytochrome P450 to the vasodilator effect of bradykinin in the rat kidney. Br J Pharmacol. 1992;107:722-725.
16. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin receptor blockade on the response to angiotensin converting enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med. 1998;339:1285-1292.
17. Yoshiaki Tsutsumi, Hiroaki Matsubara, Hiroya Masaki, Hiroki Kurihara, Satoshi Murasawa, Shinji Takai, Mizuo Miyazaki, Yoshihisa Nozawa, Ryoji Ozono, Keigo Nakagawa, et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999;104:925-935.